Sera Competitors
| SERA Stock | USD 2.65 0.03 1.12% |
Sera Prognostics vs Oncolytics Biotech Correlation
Modest diversification
The correlation between Sera Prognostics and ONCY is 0.25 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sera Prognostics and ONCY in the same portfolio, assuming nothing else is changed.
Moving against Sera Stock
| 0.64 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.48 | KRRO | Frequency Therapeutics | PairCorr |
| 0.43 | EVGN | Evogene | PairCorr |
Sera Prognostics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sera Prognostics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sera and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sera Prognostics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Sera Stock performing well and Sera Prognostics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sera Prognostics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RPID | 4.69 | 0.76 | 0.16 | 1.22 | 3.86 | 12.73 | 31.73 | |||
| STSS | 5.88 | (1.18) | 0.00 | (0.37) | 0.00 | 10.45 | 39.53 | |||
| TVGN | 4.52 | (0.99) | 0.00 | (0.39) | 0.00 | 10.00 | 26.81 | |||
| CGTX | 4.00 | (0.73) | 0.00 | (0.21) | 0.00 | 8.89 | 25.11 | |||
| ATOS | 3.85 | (1.54) | 0.00 | (1.61) | 0.00 | 6.75 | 42.59 | |||
| LUCD | 2.58 | 0.16 | 0.04 | 0.35 | 2.68 | 6.09 | 18.00 | |||
| APYX | 3.00 | 0.24 | 0.07 | 0.36 | 3.02 | 8.27 | 25.09 | |||
| SRZN | 4.62 | 1.06 | 0.21 | 0.77 | 4.66 | 13.34 | 34.29 | |||
| HURA | 6.45 | (0.75) | 0.00 | (0.06) | 0.00 | 13.89 | 50.34 | |||
| ONCY | 3.76 | (0.34) | 0.00 | (0.07) | 0.00 | 8.55 | 27.46 |
Cross Equities Net Income Analysis
Compare Sera Prognostics and related stocks such as Rapid Micro Biosystems, Sharps Technology, and Tevogen Bio Holdings Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPID | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (37.1 M) | (73.5 M) | (60.8 M) | (52.5 M) | (46.9 M) | (42.2 M) | (44.3 M) |
| STSS | (3.3 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.3 M) | (4.7 M) | (4.6 M) | (9.8 M) | (9.3 M) | (8.4 M) | (7.9 M) |
| TVGN | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 4.4 M | (60.5 M) | (10.1 M) | (9.1 M) | (9.6 M) |
| CGTX | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (10.1 M) | (11.7 M) | 757 K | (25.8 M) | (34 M) | (30.6 M) | (29 M) |
| ATOS | (122.9 K) | (3.4 M) | (5.1 M) | (10.8 M) | (14.7 M) | (15.8 M) | (6.4 M) | (8.1 M) | (11.4 M) | (17.2 M) | (17.8 M) | (20.6 M) | (26.2 M) | (30.1 M) | (25.5 M) | (23 M) | (21.8 M) |
| LUCD | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.4 M) | (8.3 M) | (28.1 M) | (56.2 M) | (52.7 M) | (45.5 M) | (41 M) | (43 M) |
| APYX | (154.1 K) | 109 K | 617 K | (4.3 M) | (17.3 M) | (5.4 M) | (4 M) | (5.1 M) | 64 M | (19.7 M) | (11.9 M) | (15.2 M) | (23.2 M) | (18.7 M) | (23.5 M) | (21.1 M) | (20.1 M) |
| SRZN | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (32.6 M) | (52.5 M) | (27.7 M) | (43 M) | (63.6 M) | (57.2 M) | (60.1 M) |
| HURA | (5.6 K) | (18.9 K) | (8.3 M) | (8.3 M) | (4.3 M) | (8.9 M) | (8.1 M) | (11.1 M) | (8 M) | (9.1 M) | (38.3 M) | (7 M) | (9.4 M) | (29.3 M) | (21.7 M) | (19.5 M) | (18.5 M) |
| ONCY | (574.5 K) | (29 M) | (36.4 M) | (23.5 M) | (18.6 M) | (13.7 M) | (15.1 M) | (15.6 M) | (17 M) | (45.6 M) | (16.8 M) | (21 M) | (19.1 M) | (20.6 M) | (31.7 M) | (28.5 M) | (27.1 M) |
Sera Prognostics and related stocks such as Rapid Micro Biosystems, Sharps Technology, and Tevogen Bio Holdings Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Sera Prognostics financial statement analysis. It represents the amount of money remaining after all of Sera Prognostics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Sera Prognostics Competitive Analysis
The better you understand Sera Prognostics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sera Prognostics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sera Prognostics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Sera Prognostics Competition Performance Charts
Five steps to successful analysis of Sera Prognostics Competition
Sera Prognostics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sera Prognostics in relation to its competition. Sera Prognostics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Sera Prognostics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sera Prognostics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sera Prognostics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Sera Prognostics position
In addition to having Sera Prognostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sera Prognostics Correlation with its peers. For information on how to trade Sera Stock refer to our How to Trade Sera Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sera Prognostics. If investors know Sera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Sera Prognostics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.76) | Revenue Per Share | Quarterly Revenue Growth (0.45) | Return On Assets | Return On Equity |
Understanding Sera Prognostics requires distinguishing between market price and book value, where the latter reflects Sera's accounting equity. The concept of intrinsic value - what Sera Prognostics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Sera Prognostics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Sera Prognostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sera Prognostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sera Prognostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.